Using data from this trial , we assessed rates of complete response at 12 months according to 5 sets of criteria , from 1 ) the trial protocol , 2 ) the Aspreva Lupus Management Study ( ALMS ) trial of mycophenolate mofetil , 3 ) the Lupus Nephritis Assessment with Rituximab ( LUNAR ) trial of rituximab , 4 ) an ongoing National Institutes of Health trial of abatacept ( Abatacept and Cyclophosphamide Combination : Efficacy and Safety Study [ ACCESS ] ) , and 5 ) published recommendations of the American College of Rheumatology .
